BRPI0913071A2 - forma grande de 2,5-oligoadenilato sintetase oas3 humana para prevenir ou tratar infecção por vírus com rna de fiota simples com senso positivo - Google Patents

forma grande de 2,5-oligoadenilato sintetase oas3 humana para prevenir ou tratar infecção por vírus com rna de fiota simples com senso positivo

Info

Publication number
BRPI0913071A2
BRPI0913071A2 BRPI0913071A BRPI0913071A BRPI0913071A2 BR PI0913071 A2 BRPI0913071 A2 BR PI0913071A2 BR PI0913071 A BRPI0913071 A BR PI0913071A BR PI0913071 A BRPI0913071 A BR PI0913071A BR PI0913071 A2 BRPI0913071 A2 BR PI0913071A2
Authority
BR
Brazil
Prior art keywords
oas3
human
prevent
stranded rna
virus infection
Prior art date
Application number
BRPI0913071A
Other languages
English (en)
Inventor
Chuansumrit Ampaiwan
Sakuntabhai Anavaj
Brehin Anne-Claire
Julier Cecile
Casademont Isabelle
Despres Philippe
Malasit Prida
Paulous Sylvie
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of BRPI0913071A2 publication Critical patent/BRPI0913071A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0913071A 2008-05-20 2009-05-20 forma grande de 2,5-oligoadenilato sintetase oas3 humana para prevenir ou tratar infecção por vírus com rna de fiota simples com senso positivo BRPI0913071A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290470A EP2123748A1 (en) 2008-05-20 2008-05-20 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
PCT/IB2009/005956 WO2009141731A2 (en) 2008-05-20 2009-05-20 The large form of human 2', 5'-oligoadenylate synthetase oas3 for preventing or treating infection with positive-sense single-stranded rna viruses

Publications (1)

Publication Number Publication Date
BRPI0913071A2 true BRPI0913071A2 (pt) 2019-09-24

Family

ID=39777103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913071A BRPI0913071A2 (pt) 2008-05-20 2009-05-20 forma grande de 2,5-oligoadenilato sintetase oas3 humana para prevenir ou tratar infecção por vírus com rna de fiota simples com senso positivo

Country Status (8)

Country Link
US (1) US20110189155A1 (pt)
EP (3) EP2123748A1 (pt)
JP (1) JP2011522527A (pt)
KR (1) KR20110049749A (pt)
CN (1) CN102124101A (pt)
BR (1) BRPI0913071A2 (pt)
CA (1) CA2725527A1 (pt)
WO (1) WO2009141731A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413838A4 (en) 2009-04-03 2012-09-19 Biomerix Corp AT LEAST PARTIALLY RESORBIBLE RETICULATED ELASTOMER MATRIX PARTICLES AND PRODUCTION METHOD
US10955414B2 (en) 2016-08-01 2021-03-23 Inbios International, Inc. Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens
JP7032775B2 (ja) * 2016-11-09 2022-03-09 公立大学法人名古屋市立大学 人工合成ｍＲＮＡの発現を効率化する方法
CN110556184B (zh) * 2019-10-09 2022-11-29 中国人民解放军总医院 基于Hessian正则非负矩阵分解的非编码RNA与疾病关系预测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
EP1306431B1 (en) * 2000-07-31 2008-03-19 Green Peptide Co., Ltd. Tumor antigen
FR2823224B1 (fr) 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
AU2002341207A1 (en) * 2001-05-08 2002-11-18 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
GB0208928D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
CA2484251C (en) * 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US20070269828A1 (en) * 2002-06-19 2007-11-22 Brinton Margo A Compositions and methods for viral resistance genes
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
EP2267154A1 (en) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate synthetase
EP1929042A4 (en) * 2005-08-23 2010-03-17 Illumigen Biosciences Inc DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO A VIRUS INFECTION, OAS2 OR OAS3
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis

Also Published As

Publication number Publication date
EP2597163A1 (en) 2013-05-29
WO2009141731A3 (en) 2010-03-11
KR20110049749A (ko) 2011-05-12
EP2123748A1 (en) 2009-11-25
JP2011522527A (ja) 2011-08-04
CA2725527A1 (en) 2009-11-26
US20110189155A1 (en) 2011-08-04
CN102124101A (zh) 2011-07-13
WO2009141731A2 (en) 2009-11-26
EP2294189A2 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
LTPA2018016I1 (lt) Susiūti katijonų mainų polimerai, kompozicijos ir panaudojimas hiperkalemijos gydyme
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
SMT201600273B (it) Genz 112638 per trattare la malattia di gaucher o fabry in terapia di combinazione
BRPI0906975A2 (pt) Escova de dente para o tratamento e/ou detecção de micróbios
BRPI0920026A2 (pt) método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos.
BRPI0817922A2 (pt) Composição, e, processo de promover e/ou de manter saúde sistêmica
BRPI0907422A2 (pt) Composições de limpeza e/ou tratamento
BRPI0811710A2 (pt) Troca de nucleotídeo alvo com oligonucleotídes modificados melhorados
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0823271A2 (pt) Chip de dna, kit para detecção ou para genotipagem de bactérias que causam doenças sexualmente transmitidas, genotipagem de resistência a fármacos antibacterianos e método de detecção ou de genotipagem das mesmas.
BRPI0911004A2 (pt) Artigo antimicrobiano, líquido de tratamento e métodos de preparação dos mesmos
BRPI0917321A2 (pt) prevenção, tratamento e diagnóstico de infecção por p. gingivalis
BRPI0810227A2 (pt) Tratamento de água com baixo potencial de incrustação
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
FR2918570B1 (fr) DIGLYCATION DES AGEs.
BRPI0819875A2 (pt) processo de produção de eletrodo para deionização capacitiva, eletrodo para deionização capacitiva, sistema purificador de água e dispositivo purificador.
EA201101477A1 (ru) Органические соединения и их применение
FR2934129B1 (fr) Procede de traitement cosmetique.
BR112013020019A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2.
BRPI1013714A2 (pt) prendedor com aba nervurada.
BRPI0821352A2 (pt) Tratamento de batateiros e bananeiras com composições antifúngicas
PL2349245T3 (pl) Leczenie utajonego zakażenia wirusem hiv-1 za pomocą auranofiny lub tritlenku diarsenu
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
BRPI0722060A2 (pt) Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.